ZTZhe Tang

Zhe Tang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zhe Tang has a total of 152 co-authors. Here are the top co-authors by number of shared publications:

  • Honghe Zhang

    Department of Pathology, Research Unit of Intelligence Classification of Tumor Pathology and Precision Therapy, Chinese Academy of Medical Sciences, Zhejiang University School of Medicine, Hangzhou, China

    6 shared publications
  • Qiao Jin

    Zhejiang University

    6 shared publications
  • Fengyan Han

    Department of Pathology and International Institutes of Medicine, The Fourth Affiliated Hospital (Yiwu), Zhejiang University School of Medicine, Hangzhou, China

    5 shared publications
  • Lei Lei

    Department of Surgery and International School of Medicine International Institutes of Medicine the Fourth Affiliated Hospital of School of Medicine Zhejiang University Yiwu China

    5 shared publications
  • Min Zhou

    Institute of Translational Medicine, Zhejiang University, HangZhou, CHINA

    5 shared publications
  • Shaomin Zou

    Department of Surgery, Center for Cancer Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University

    5 shared publications

Latest Publications

  • Open Access

    Molecular innate immune programs of tumor-associated macrophages in immune checkpoint blockade resistance: a staged framework from suppressive circuitry to translational bottlenecks

    by Yuzhe Huang, Junqi Zhang, Kaipeng Tu, Wenfeng Ye, Shaomin Zou, Zhe Tang, Cheng Zeng

    Immune checkpoint blockade (ICB) has reshaped the treatment landscape for many malignancies, yet only a subset of patients achieve durable clinical benefit. Both primary and acquired resistance remain major barriers to long-term disease control. As central innate immune cells in the tumor microenvironment, tumor-associated macrophages (TAMs) have emerged as key contributors to this resistance. Beyond their well-recognized role in suppressing T-cell responses, TAMs influence stromal organization, metabolic stress, checkpoint ligand expression, and phagocytic activity within the TME. They also affect the intratumoral distribution and clearance of therapeutic antibodies. In this review, we discuss TAM-mediated resistance to ICB as a molecularly regulated innate immune process that is dynamic and adaptive. We consider how macrophages are recruited to tumors, how they are educated by local microenvironmental cues, and how innate immune signaling, metabolic regulation, and phagocytic checkpoints shape suppressive programs that limit the efficacy of ICB. This framework allows us to distinguish macrophage programs that recur across tumor types from those shaped by specific tissue contexts or tumor lineages, and to place diverse TAM subsets within a clinically relevant model of ICB resistance. We also review current TAM-directed therapeutic strategies, including CSF1/CSF1R blockade, inhibition of chemokine-dependent recruitment, metabolic and epigenetic reprogramming, targeting of phagocytosis checkpoints, and emerging delivery-based approaches. Although these strategies are supported by substantial mechanistic evidence, their clinical activity has so far been variable. This inconsistency likely reflects the marked heterogeneity and plasticity of TAMs, compensatory signaling pathways, spatial constraints within tumors, treatment-induced adaptation, toxicity, and the lack of robust biomarkers for patient selection. We propose that future TAM-directed therapies should move beyond broad macrophage depletion or nonspecific suppression. Instead, more precise approaches are needed—ones that are matched to dominant macrophage programs, informed by spatial and functional profiling, and guided by predictive biomarkers. Such strategies may help preserve beneficial innate immune macrophage functions while selectively disrupting the TAM states that sustain resistance to ICB.


  • Open Access

    Microalgae Hybrid Biosystem for Enhanced Oral Delivery of Rifaximin in Hepatic Encephalopathy Treatment

    by Kaiyue Wang, Xueting Huang, Lingxiao Yang, Jin Liu, Lei Lei, Shaomin Zou, Kai Wang, Min Zhou, Zhe Tang

    Hepatic encephalopathy (HE) is a serious neuropsychiatric complication of acute or chronic liver failure. It occurred in approximately 40% of acute liver failure cases and affected 30%–45% of patients with chronic liver failure or decompensated cirrhosis. Hyperammonemia is widely recognized as a central pathogenic factor in the pathogenesis of HE. Rifaximin (RIF), a non‐absorbable oral antibiotic, was widely used to manage HE by modulating gut microbiota and reducing ammonia production. However, its clinical efficacy remained suboptimal due to poor aqueous solubility, limited dispersibility, and inadequate gastrointestinal retention. These limitations were further exacerbated in severe cases, owing to restricted oral dosing, recurrence associated with poor adherence, and potential risks of antimicrobial resistance and infection‐related adverse events. This study presented a microalgae‐nanoparticle hybrid system (SP@RIF) for drug delivery, in which RIF‐encapsulated nanoparticles (RIFnano) were electrostatically loaded onto the surface of Spirulina platensis (SP), aiming to improve the oral delivery and therapeutic efficiency in HE treatment. RIFnano exhibited significantly enhanced antibacterial activity compared to free RIF. SP@RIF demonstrated prolonged gastrointestinal retention and sustained drug release profiles. In mouse models of HE, oral administration of SP@RIF markedly reduced systemic ammonia levels and improved behavioral outcomes. Furthermore, SP@RIF enhanced intestinal barrier function, attenuated systemic inflammation and neuroinflammation, ameliorated cognitive impairments, and modulated the gut microbiota. Importantly, these therapeutic benefits were achieved without observable toxicity. These findings highlight SP@RIF as a potential therapeutic strategy for treating HE.

  • Open Access

    Neutrophil extracellular traps drive local tumor progression and metastasis following thermal ablation in liver cancer via TLR9-mediated inflammatory feedback and immunosuppression

    by Zhou Tian, Jinchao Zhao, Yueyang Wang, Shaomin Zou, Junkang Ding, Tangye Zeng, Yizhao Zhou, Bo Zhang, Honghe Zhang, Zhe Tang

    Background: Local tumor progression and metastasis substantially compromise the therapeutic efficacy of thermal ablation in liver cancer. Although the inflammatory microenvironment contributes, the specific role of neutrophils after ablation remains unclear. This study aimed to clarify the roles of neutrophil extracellular traps (NETs) after thermal ablation and evaluate the translational potential of NETs-targeted strategies. Methods: The adverse prognostic impact of thermal ablation-induced neutrophil and inflammatory changes in liver cancer was retrospectively evaluated. Circulating NETs were quantified by ELISA, and their association with local tumor progression was analyzed. An orthotopic liver cancer mouse model and patient-derived neutrophils elucidated the spatiotemporal dynamics and mechanisms of ablation-induced NETs, and pharmacologic inhibition was used to investigate NET formation, function, and translational potential. Results: Thermal ablation rapidly activates neutrophils, elicits a sustained local inflammatory response and NET formation, which is closely associated with poor prognosis in patients with liver cancer. Depletion of neutrophils, inhibition of NET formation, or degradation of thermal ablation-induced NETs markedly suppressed post-ablation tumor progression. Mechanistically, tumor cell-intrinsic reactive oxygen species generated under heat stress contributed to nuclear factor kappa-B (NF-κB) activation, promoting p65 binding to theC-X-C motif chemokine ligand 1 (CXCL1) promoter and transcriptional upregulation of CXCL1. This process drove CXCL1-C-X-C motif chemokine receptor 2 (CXCR2) signaling and led to the formation of a characteristic band-like NETs-enriched zone at the peri-ablational margin. In turn, NETs activated toll-like receptor (TLR)9-dependent NF-κB,mitogen-activated protein kinase (MAPK), and signal transducer and activator of transcription 3 (STAT3) signaling in heat-stressed cancer cells, reinforcing a pro-inflammatory feedback loop. Concurrently, NETs impaired CD8 + T-cell responses and fostered an immunosuppressive microenvironment. Together, this coordinated pro-inflammatory and immunosuppressive effect promotes liver cancer progression following thermal ablation, which can be effectively reversed by dual blockade of NF-κB and CXCR2. Conclusions: Our research uncovers a novel mechanism underlying tumor-promoting inflammation after thermal ablation, highlighting the critical role of NETs as mediators through TLR9 activation of downstream inflammatory pathways and the significant potential of NETs-targeted strategies in combination with thermal ablation.


  • Open Access

    Supplementary Data from AFDN Deficiency Promotes Liver Tropism of Metastatic Colorectal Cancer

    by Shaoxia Liao, Jingwen Deng, Mengli Deng, Chaoyi Chen, Fengyan Han, Kehong Ye, Chenxia Wu, Lvyuan Pan, Maode Lai, Zhe Tang, et al.

    Table S1. Information on the sequences of shRNAs, sgRNAs, and siRNAs;Table S2. Information of sequences for primers; Table S3. Information of primary antibodies;Figure S1. Expression levels of AFDN in the GEO database; Figure S2. AFDN deficiency promotes CRC cells migration and invasion; Figure S3. Snail knockdown did not reduce CRC cells migration and invasion induced by AFDN deficiency; Figure S4. CXCR4 expression was increased in AFDN-deficient cells.

  • Open Access

    Data from AFDN Deficiency Promotes Liver Tropism of Metastatic Colorectal Cancer

    by Shaoxia Liao, Jingwen Deng, Mengli Deng, Chaoyi Chen, Fengyan Han, Kehong Ye, Chenxia Wu, Lvyuan Pan, Maode Lai, Zhe Tang, et al.

    Liver metastasis is a major cause of morbidity and mortality in patients with colorectal cancer. A better understanding of the biological mechanisms underlying liver tropism and metastasis in colorectal cancer could help to identify improved prevention and treatment strategies. In this study, we performed genome-wide CRISPR loss-of-function screening in a mouse colorectal cancer model and identified deficiency of AFDN, a protein involved in establishing and maintaining cell–cell contacts, as a driver of liver metastasis. Elevated AFDN expression was correlated with prolonged survival in patients with colorectal cancer. AFDN-deficient colorectal cancer cells preferentially metastasized to the liver but not in the lungs. AFDN loss in colorectal cancer cells at the primary site promoted cancer cell migration and invasion by disrupting tight intercellular junctions. Additionally, CXCR4 expression was increased in AFDN-deficient colorectal cancer cells via the JAK-STAT signaling pathway, which reduced the motility of AFDN-deficient colorectal cancer cells and facilitated their colonization of the liver. Collectively, these data shed light on the mechanism by which AFDN deficiency promotes liver tropism in metastatic colorectal cancer.Significance:A CRISPR screen reveals AFDN loss as a mediator of liver tropism in colorectal cancer metastasis by decreasing tight junctions in the primary tumor and increasing interactions between cancer cells and hepatocytes.

  • Open Access

    A neutrophil-tumor cascade-targeting Trojan horse for heterobifunctional prodrug delivery to enhance cGAS-STING cancer immunotherapy

    by Huamiao Zhang, Yang Li, Qiuchen Bi, Heping Zhu, Huiwen Wang, Zhao Wang, Zhangqiang Ma, Huiping Liu, Xiaoling Zhu, Jiaqi Cao, et al.

    Since the discovery of the cGAS-STING pathway, attempts to utilize it as an anti-tumor immunotherapy have attracted significant research interest and inves

  • DNA-inspired conjugated polymer biointerface for selective tumor cell capture and noninvasive release

    by Misbah Waheed, Kanthasamy Raagulan, Cheng Zeng, Wuyi Liu, Lin Zhang, Zhe Tang

  • Open Access

    Fe-MOF loaded with capmatinib to reverse immunosuppressive microenvironment and inhibit tumor metastasis after radiofrequency ablation

    by Jinchao Zhao, Lei Lei, Cheng Zeng, Xianfei Zhou, Junkang Ding, Wenbin Dai, Angfeng Jiang, Shaomin Zou, Qiao Jin, Zhe Tang

    Incomplete radiofrequency ablation (iRFA) of hepatocellular carcinoma (HCC) has the risk to exacerbate the tumor immunosuppressive microenvironment and promote lung metastasis. There is an urgent need to reverse the immunosuppressive microenvironment and reduce lung metastasis after iRFA. Herein, an iron-based metal-organic framework loaded with capmatinib (Fe-MOF/Cap) is employed to reverse the immunosuppressive microenvironment dominated by M2-like tumor-associated macrophages (TAMs) after iRFA and inhibit lung metastasis of HCC. On one hand, Fe-MOF/Cap repolarizes M2-like TAMs to M1-like TAMs and inhibits the expression of PD-L1 after iRFA, promoting CD8+ T cell infiltration. The infiltration of CD8+ T cells and the decrease of PD-L1 are conducive to enhance the immunotherapy after iRFA. On the other hand, Fe-MOF/Cap can inhibit lung metastasis of HCC via inhibiting the expression of c-MET. In vitro and in vivo experiments confirm that Fe-MOF/Cap is able to significantly inhibit the lung metastasis of HCC after iRFA by inhibiting the c-MET/STAT3/VEGF pathway. Fe-MOF/Cap provides a potentially promising strategy for HCC immunotherapy and anti-metastasis after iRFA, with favorable clinical prospects.


  • Open Access

    Crosstalk between dysregulated amino acid sensing and glucose and lipid metabolism in colorectal cancer

    by Danning Wang, Shaomin Zou, Junkang Ding, Chang Gao, Jianwei Wang, Zhe Tang

    Cancer cells reprogram the metabolism of glucose, lipids, and proteins (amino acids) to meet their energy needs during tumor initiation and progression. Amino acid sensing pathways play rucial roles in the progression and spread of colorectal cancer (CRC), but the crosstalk between these pathways and glucose and lipid metabolism has not been systematically elucidated. We summarize the roles of key amino acids in CRC, the corresponding nutrient sensors, the associated dysregulated signaling pathways, and their subcellular localization. Furthermore, we highlight how disrupted amino acid sensing forms an integrated regulatory network that modulates glucose and lipid metabolism through multiple signaling cascades. These insights reveal both opportunities for clinical translation and unresolved challenges in the field. We believe that this comprehensive review will stimulate further research in this emerging area and draw significant attention from both the scientific community and broader audiences. This review aims to identify new diagnostic markers, therapeutic targets, and prognostic indicators by enhancing the understanding of nutrient metabolic pathway interactions.


  • Open Access

    Autophagy‐Targeting Nanomedicine: Strike at the Heart of the Cancer via Precise Modulation of Autophagy

    by Zhouyi Sun, Huali Zuo, Kai Zhang, Yang Liu, Qianwen Wang, Qitao Hu, Jiwei Qian, Andreas Lundqvist, Bo Zhang, Weiyu Chen, et al.

    Autophagy is a process of engulfing cytoplasmic proteins or organelles, thereby fulfilling cells’ metabolic needs and the renewal of specific organelles. Given its key roles in tumor progression, autophagy has attracted tremendous attention in cancer therapies. Notably, there is a megatrend to integrating autophagy regulation into mainstream treatments. This review focuses on autophagy‐targeting nanomedicine (ApT‐NM) to modulate autophagy in tumor therapy, including the unmodified and functionalized nanoparticles that target tumors by carrying autophagy modulators. On the one hand, it can reverse treatment resistance by inhibiting protective autophagy, and on the other hand, it can promote the death of cancer cells through type II apoptosis by inducing autophagy. Moreover, advanced nanoplatforms combining various treatments (such as chemotherapy, radiotherapy, photothermal therapy, and photodynamic therapy, etc.) have also been summarized. Last, the future perspectives and directions for ApT‐NM research are provided, hoping to emphasize this rising filed and promote the development of ApT‐NM.